SG11202012889QA - Dosing regimens for treating hypoxia-associated tissue damage - Google Patents

Dosing regimens for treating hypoxia-associated tissue damage

Info

Publication number
SG11202012889QA
SG11202012889QA SG11202012889QA SG11202012889QA SG11202012889QA SG 11202012889Q A SG11202012889Q A SG 11202012889QA SG 11202012889Q A SG11202012889Q A SG 11202012889QA SG 11202012889Q A SG11202012889Q A SG 11202012889QA SG 11202012889Q A SG11202012889Q A SG 11202012889QA
Authority
SG
Singapore
Prior art keywords
tissue damage
dosing regimens
associated tissue
treating hypoxia
hypoxia
Prior art date
Application number
SG11202012889QA
Inventor
Lynne Robertson
Original Assignee
Temple Therapeutics BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Therapeutics BV filed Critical Temple Therapeutics BV
Publication of SG11202012889QA publication Critical patent/SG11202012889QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/145—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/21—Acids
    • A61L2300/214—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
SG11202012889QA 2018-07-03 2019-06-27 Dosing regimens for treating hypoxia-associated tissue damage SG11202012889QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/027,080 US10500318B1 (en) 2018-07-03 2018-07-03 Dosing regimens for treating hypoxia-associated tissue damage
PCT/IB2019/000849 WO2020008266A1 (en) 2018-07-03 2019-06-27 Dosing regimens for treating hypoxia-associated tissue damage

Publications (1)

Publication Number Publication Date
SG11202012889QA true SG11202012889QA (en) 2021-01-28

Family

ID=68382463

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012889QA SG11202012889QA (en) 2018-07-03 2019-06-27 Dosing regimens for treating hypoxia-associated tissue damage

Country Status (12)

Country Link
US (1) US10500318B1 (en)
EP (1) EP3817721A1 (en)
JP (2) JP7292388B2 (en)
KR (1) KR102586281B1 (en)
CN (1) CN112384197A (en)
AU (2) AU2019297094B2 (en)
BR (1) BR112020026916A2 (en)
CA (1) CA3104843C (en)
MX (1) MX2021000207A (en)
NZ (1) NZ771293A (en)
SG (1) SG11202012889QA (en)
WO (1) WO2020008266A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217400A1 (en) * 2021-05-07 2022-11-10 Nilabh GHOSH Methods of treating fibrosis and hypoxia-associated damage to peripheral nerves

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693671A (en) 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
US6797729B1 (en) 1996-06-28 2004-09-28 Baxter International Inc. Therapeutic glutamine and N-actyl-cysteine composition
CA2302017C (en) 1997-08-25 2007-01-30 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors
US6613070B2 (en) 1998-08-04 2003-09-02 Baxter International Inc. System and method for sealing vascular penetrations with hemostatic gels
US6852541B2 (en) 2001-01-19 2005-02-08 Adebola Obayan Rapid assay for testing overall oxidative stress
EP2324834B1 (en) * 2001-12-06 2019-05-08 Fibrogen, Inc. Methods of Increasing Endogenous Erythropoietin (EPO)
ES2355159T3 (en) * 2005-08-11 2011-03-23 University Of Saskatchewan REDUCTION IN THE FORMATION OF POSTOPERATIVE ADHERENCES WITH INTRAPERITONEAL GLUTAMINE.
CA2578647A1 (en) * 2007-02-15 2008-08-15 University Of Saskatchewan Reducing post-operative adhesion formation with intraperitoneal glutamine
CN101965357B (en) * 2007-08-15 2014-11-05 特拉维夫大学拉莫特有限公司 Polypeptides, matrices, hydrogels and methods of using same for tissue regeneration and repair
KR101859124B1 (en) 2010-05-03 2018-05-21 더 텍사스 에이 & 엠 유니버시티 시스템 Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases
US20180236035A1 (en) 2010-05-03 2018-08-23 Scott & White Healthcare Protein therapy for treatment of retinal diseases
US8759298B2 (en) 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration
AU2011274224A1 (en) * 2010-06-28 2013-01-17 AdeTherapeutics, Inc Keloid treatment
WO2014053542A1 (en) 2012-10-02 2014-04-10 Dsm Ip Assets B.V. Drug delivery composition comprising proteins and biodegradable polyesteramides
EP2908910A4 (en) 2012-10-17 2016-06-29 Texas A & M Univ Sys Treatment of brain injury or trauma with tsg-6 protein
FR3004353B1 (en) * 2013-04-10 2015-05-15 Fabre Pierre Dermo Cosmetique SYNERGISTIC ASSOCIATION OF ALANINE-GLUTAMINE, HYALURONIC ACID AND OAT EXTRACT, AND USE THEREOF IN A COMPOSITION FOR SCALING AND REPAIRING SKIN LESIONS
ES2941460T3 (en) * 2014-03-07 2023-05-23 Mark Tuffley Composition and method for improving wound healing
US10450596B2 (en) * 2014-03-28 2019-10-22 Memorial Sloan-Kettering Cancer Center L-2-hydroxyglutarate and stress induced metabolism
US10351825B2 (en) 2014-07-11 2019-07-16 The Texas A&M University System Mesenchymal stem cells derived from induced pluripotent stem cells
US20180296631A1 (en) * 2017-04-12 2018-10-18 University Of Toronto Hydrogel composition and associated method of use

Also Published As

Publication number Publication date
AU2019297094A1 (en) 2021-01-14
WO2020008266A1 (en) 2020-01-09
EP3817721A1 (en) 2021-05-12
JP7292388B2 (en) 2023-06-16
MX2021000207A (en) 2021-06-18
KR102586281B1 (en) 2023-10-11
CA3104843C (en) 2023-09-12
NZ771293A (en) 2024-03-22
JP2021529837A (en) 2021-11-04
CN112384197A (en) 2021-02-19
JP2023063301A (en) 2023-05-09
US10500318B1 (en) 2019-12-10
BR112020026916A2 (en) 2021-03-30
KR20210030948A (en) 2021-03-18
AU2023200154A1 (en) 2023-02-09
AU2019297094B2 (en) 2022-10-13
CA3104843A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
GB201820166D0 (en) Therapeutic agents
GB201820165D0 (en) Therapeutic agents
IL278247B (en) Mct4 inhibitors for treating disease
HK1253238A1 (en) Gls1 inhibitors for treating disease
ZA201908603B (en) Hair compositions for damage treatment
GB201512733D0 (en) Therapeutic agents for treating conditions associated with elevated GDF15
EP3618783C0 (en) Devices for treating eyelids
GB201813876D0 (en) Treatment
GB201805816D0 (en) Therapeutic agents
CA187950S (en) Pet treat
IL276577A (en) Methods for treating cardiac injury
IL281792A (en) Treatment methods
IL288937A (en) Improved treatment using eyp001
IL272738A (en) Treatment regimens
GB201800546D0 (en) Treatment
IL280515A (en) Dosing regimens for elagolix
IL281839A (en) Treatment methods
IL276718A (en) Apparatus for treating submucosal tissue
IL266292A (en) Treatment regimens
SG11202012889QA (en) Dosing regimens for treating hypoxia-associated tissue damage
SG11202003127WA (en) Methods for treating lymphomas
GB2581986B (en) Animal footbath apparatus
SG10201910408QA (en) Device for treating dysarthrosis
IL278984A (en) Safinamide for treating myotonia
GB2571849B (en) Treatments for cachexia